Therapeutic antibodies

Question 1

Targets VEGF

Answer 1

Bevacizumab - treats CRC, RCCA

Question 2

Targets EGFR

Answer 2

Cetuximab, treats CRC, head and neck cancer

Question 3

Targets HER2/neu

Answer 3

Trastuzumab, treats breast cancer

Question 4

Autoimmune disease therapy

Answer 4

Adalimumab, infliximab - targets TNF-alpha, treats IBD, RA, ankylosing spondylitis, psoriasis; Etanercept has same effect but is decoy TNF alpha receptor

Eculizumab - targets C5 to treat PNH

Natalizumab - targets alpha4-integrin, treats MS and Crohn dz

Question 5

Disrupts WBC adhesion

Answer 5

Natalizumab (by inhibiting alpha4-integrin) - can –> PML in pts with JC virus

Question 6

Abciximab

Answer 6

Targets plt glycoproteins IIb/IIIa - prevents ischemic complications during PCI

Question 7

Denosumab

Answer 7

Targets RANKL - inhibits OC maturation to treat osteoporosis

Question 8

Digoxin immune Fab

Answer 8

Targets digoxin - antidote for toxicity

Question 9

Omalizumab

Answer 9

Targets IgE to treat allergic asthma

Question 10

Palivizumab

Answer 10

Targets RSV F protein to prophylax high-risk infants

Question 11

Ranibizumab, bevacizumab

Answer 11

Target VEGF and treat neovascular age-related macular degeneration

Question 12

Cancer therapies

Answer 12

Alemtuzumab (targets CD52, treats CLL)

Bevacizumab (targets VEGF, treats CRC, RCCA)

Cetuximab (targets EGFR, treats CRC, head and neck ca)

Rituximab (targets CD20, treats B cell NHL, CLL, RA, ITP)

Trastuzumab (targets HER2/neu, treats breast cancer) - “tras2zumab”